Advertisement
CSL Behring
Subscribe to CSL Behring

The Lead

CSL Behring's Grassroots Advocacy Grants Promote Early Diagnosis and Access to Care for Patients with Rare Diseases

January 30, 2013 4:21 am | by CSL Behring | News | Comments

CSL Behring announced today that it has awarded $78,750 in Local Empowerment for Advocacy Development (LEAD) grants to patient advocacy organizations in New York and Ohio, and to the American Plasma Users Coalition (APLUS). LEAD grants are intended to help local patient organizations...

CSL Behring Enrolls First Patient in Global Pediatric Phase III Pivotal Study of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) to Treat Hemoph...

January 21, 2013 5:21 am | by CSL Behring | News | Comments

CSL Behring has announced that the first patient has been enrolled in the pivotal pediatric phase...

New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease

January 21, 2013 5:21 am | by CSL Behring | News | Comments

Treatment with albumin reduces renal impairment and mortality in cirrhotic patients with...

CSL Behring Seeks Proposals for the Third Annual Interlaken Leadership Awards

January 14, 2013 4:21 am | by CSL Behring | News | Comments

Committed to improving the quality of life for people with rare and serious diseases, CSL Behring...

View Sample

FREE Email Newsletter

CSL Behring and its Employees Give Back to their Communities by Supporting a Range of Charities Year-Round

January 4, 2013 5:22 am | by CSL Behring | News | Comments

CSL Behring and its employees helped numerous organizations throughout the United States in 2012, from local United Way chapters to patient advocacy groups, food banks and other agencies that provide vital services to people in need. With operations in King of Prussia, Pa., Kankakee, Ill....

Phase II Study Indicates that Fibrinogen Concentrate Given as a First-Line Therapy Safely Reduces Need for Transfusion after Aortic Surgery

December 19, 2012 6:21 pm | by CSL Behring | News | Comments

Clinical study results published today in the journal Anesthesiology showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery.

CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report

December 4, 2012 10:21 pm | by CSL Behring | News | Comments

CSL Behring’s parent company, CSL Limited (ASX:CSL), reaffirms the company’s commitment to responsible business practice and sustainable development in its fourth Corporate Responsibility Report – Our Corporate Responsibility 2012. The report details CSL’s performance across key corporate...

Advertisement

Analysis Finds Improvements in Health-Related Quality of Life for Hereditary Angioedema Patients Treated with C1-Inhibitor

November 14, 2012 5:21 pm | by CSL Behring | News | Comments

A high level of health-related quality of life (HRQoL) is achievable for patients managing hereditary angioedema (HAE), a rare and serious genetic disorder, when effective treatment such as C1-inhibitor (INH) concentrate is available, according to a prospective patient assessment...

Study Supports Efficacy, Safety of Hizentra® in Japanese Patients with Primary Immunodeficiency Disease

October 4, 2012 1:22 am | by CSL Behring | News | Comments

A new study conducted in Japan supports the previously demonstrated safety and efficacy of Hizentra® (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID). The data were presented today at the 15th Biennial Meeting of the European Society for...

New Model Compares Economic Value of Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin

October 4, 2012 1:21 am | by CSL Behring | News | Comments

Analysis using a new economic model demonstrates that higher dosing of subcutaneous immunoglobulin therapy (SCIg) is a cost-effective alternative to intravenous IgG replacement therapy (IVIG) in patients with primary immunodeficiencies (PID). The analysis shows higher doses of SCIg are...

Avery-Landsteiner Prize for Immunology Awarded to Alain Fischer of Paris, France, by German Society for Immunology

September 7, 2012 6:22 am | by CSL Behring | News | Comments

The German Society for Immunology (DGfI) has awarded its 2012 Avery-Landsteiner Prize to Alain Fischer, M.D., Ph.D., of Paris, France, for his milestone discoveries and treatment developments in the management of hereditary immunodeficiencies. The Prize was presented at the European...

CSL Behring Awards Advocacy Grants to Patient Groups in Six States: NC, CA, WA, PA, IL, NY

August 1, 2012 6:22 am | by CSL Behring | News | Comments

CSL Behring announced today that it has awarded six patient advocacy organizations in the U.S. with Local Empowerment for Advocacy Development (LEAD) grants totaling nearly $70,000. LEAD grants are awarded semiannually and are intended to help local patient organizations achieve their...

Advertisement

Jeffrey Modell Foundation Opens Diagnostic Center forPrimary Immunodeficiencies at Midwest Immunology Clinic

July 26, 2012 8:21 am | by CSL Behring | News | Comments

The Jeffrey Modell Foundation (JMF), in partnership with CSL Behring, has designated the Midwest Immunology Clinic in Plymouth, Minnesota as a Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies (PI). The Center is headed by Ralph Shapiro, M.D. and is devoted to the diagnosis,...

PRIMA Study Shows Treatment with Privigen® Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

June 27, 2012 10:21 am | by CSL Behring | News | Comments

Rotterdam, Netherlands — 27 June — Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen® [Immune Globulin Intravenous...

CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)

June 8, 2012 1:21 pm | by CSL Behring | News | Comments

CSL Behring announced today that the company has been granted orphan drug designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The Orphan Drug Designation is granted for the...

CSL Behring Submits Marketing Authorization Variation Application to European Medicines Agency (EMA) for Privigen® in Chronic Inflammatory Demyelinating Polyradiculoneuropathy...

May 31, 2012 7:22 am | by CSL Behring | News | Comments

CSL Behring announced today that it has submitted a Variation Application to the European Medicines Agency (EMA) for the use of Privigen® (immune globulin intravenous [human], 10 percent liquid for intravenous administration) in Chronic Inflammatory Demyelinating Polyradiculoneuropathy...

CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy

May 29, 2012 2:22 pm | by CSL Behring | News | Comments

CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review its Biologics License Application (BLA) for a human 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of vitamin K-antagonist therapy (i.e., warfarin) in...

Advertisement

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase inhibitor in Patients with Hereditary Angioedema

May 5, 2012 12:22 pm | by CSL Behring | News | Comments

CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema (HAE). Part of the COMPACT (Clinical Studies for Optimal Management in...

CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care

May 5, 2012 12:22 pm | by CSL Behring | News | Comments

Data presented today by CSL Behring at the 2012 Thrombosis and Hemostasis Summit of North America (THSNA) showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping bleeding in patients receiving vitamin K...

Analysis Finds Safety of 4-Factor Prothrombin Complex Concentrate Is Consistent With the Current Standard Treatment for Vitamin K Antagonist Reversal

May 5, 2012 12:22 pm | by CSL Behring | News | Comments

Data presented by CSL Behring today at the 2012 Thrombosis and Hemostasis Summit of North America (THSNA) showed that the safety profile of human 4-factor prothrombin complex concentrate (PCC) is consistent with the current standard of treatment in patients receiving vitamin K antagonist...

Xencor Receives Milestone Payment from CSL Limited Under Antibody Optimization Collaboration

April 19, 2012 4:06 am | News | Comments

Xencor, Inc. announced today that the company received a milestone payment under an antibody optimization collaboration agreement with CSL Limited.  The payment was triggered by filing of an investigational new drug application with the FDA for a novel monoclonal antibody that was optimized using Xencor's XmAb antibody engineering technology. 

HealthyWomen Asks: Do You Know the Signs and Symptoms of Von Willebrand Disease (VWD)?

April 18, 2012 11:22 am | by CSL Behring | News | Comments

Although von Willebrand disease (VWD) is the most common hereditary bleeding disorder in the United States, affecting up to 1 percent of the population, it is often misdiagnosed or under-diagnosed in women. HealthyWomen, the nation's leading nonprofit health information source for women,...

CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period

April 16, 2012 1:22 pm | by CSL Behring | News | Comments

To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in...

CSL Behring Commences Phase I study with rVIIa-FP, a Novel Therapy to Treat People With Hemophilia A and Hemophilia B Who Have Inhibitors

April 5, 2012 1:21 am | by CSL Behring | News | Comments

CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Phase I study will investigate in healthy volunteers the safety and pharmacokinetics of rVIIa-FP in comparison to placebo. CSL Behring, in...

Findings Confirm Benefits of Albumin in Treating Cirrhosis Patients Undergoing Large-Volume Paracentesis

April 2, 2012 6:22 pm | by CSL Behring | News | Comments

Administration of albumin reduces morbidity and mortality in cirrhotic patients undergoing large-volume paracentesis due to severe ascites, according to a new meta-analysis published online today in Hepatology, the official journal of the American Association for the Study of Liver...

First patient dosed in CSL Behring global Phase II/III pivotal study of recombinant fusion protein linking coagulation factor IX with recombinant albumin

March 21, 2012 2:22 pm | by CSL Behring | News | Comments

CSL Behring has announced that the first patient has been dosed in a phase II/III, prospective, open-label, multi-center study designed to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The...

CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery

March 15, 2012 3:22 pm | by CSL Behring | News | Comments

CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

CSL Behring Recognized As A "Pioneer" By European OrganisationFor Rare Diseases (EURORDIS)

March 7, 2012 6:22 pm | by CSL Behring | News | Comments

CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat...

Analysis Finds Bioavailability of IgG Is Consistent, Regardless of Formulation

March 7, 2012 6:22 pm | by CSL Behring | News | Comments

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route. The analysis, which was presented at the 2012 American...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading